| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
Lancet Oncol
|
2010
|
13.25
|
|
2
|
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
|
J Clin Oncol
|
2012
|
3.95
|
|
3
|
Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2011
|
2.05
|
|
4
|
Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.
|
Cancer
|
2009
|
1.52
|
|
5
|
[Treatment of unresectable locally advanced pancreatic cancer with combined radiotherapy and chemotherapy].
|
Ugeskr Laeger
|
2008
|
1.37
|
|
6
|
Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
|
Acta Oncol
|
2005
|
1.15
|
|
7
|
Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
|
Oncologist
|
2008
|
1.11
|
|
8
|
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
|
Lung Cancer
|
2007
|
0.99
|
|
9
|
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
|
BMC Cancer
|
2012
|
0.98
|
|
10
|
Why are some patients in treatment for advanced cancer reluctant to consult their GP?
|
Scand J Prim Health Care
|
2009
|
0.95
|
|
11
|
High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
|
Mol Oncol
|
2013
|
0.92
|
|
12
|
Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.
|
PLoS One
|
2013
|
0.86
|
|
13
|
Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.
|
Gastric Cancer
|
2011
|
0.84
|
|
14
|
Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much?
|
Acta Oncol
|
2015
|
0.83
|
|
15
|
Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?
|
Ann Surg
|
2015
|
0.83
|
|
16
|
[Chemotherapy to patients with metastatic carcinoma of the esophagus and gastro-esophageal junction. A survey of a Cochrane review].
|
Ugeskr Laeger
|
2008
|
0.82
|
|
17
|
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
|
Acta Oncol
|
2010
|
0.81
|
|
18
|
High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
|
Acta Oncol
|
2012
|
0.81
|
|
19
|
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.
|
Acta Oncol
|
2011
|
0.80
|
|
20
|
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
|
Acta Oncol
|
2007
|
0.79
|
|
21
|
Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
|
Acta Oncol
|
2011
|
0.78
|
|
22
|
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
|
Acta Oncol
|
2010
|
0.78
|
|
23
|
Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab.
|
Cancer Biol Ther
|
2011
|
0.78
|
|
24
|
Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
|
Acta Oncol
|
2008
|
0.77
|
|
25
|
Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports.
|
Acta Oncol
|
2006
|
0.76
|
|
26
|
Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer.
|
Radiother Oncol
|
2009
|
0.76
|
|
27
|
Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancer.
|
Acta Oncol
|
2011
|
0.76
|
|
28
|
New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin.
|
Chemotherapy
|
2016
|
0.76
|
|
29
|
In reply to Parlak and Topkan. Re: Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.75
|
|
30
|
[Hepatocellular carcinoma and other liver tumors].
|
Ugeskr Laeger
|
2006
|
0.75
|
|
31
|
How to overcome resistance to therapy?
|
J Gastrointest Oncol
|
2012
|
0.75
|
|
32
|
A multidisciplinary approach to the treatment of colorectal liver metastases is mandatory.
|
Acta Radiol
|
2009
|
0.75
|
|
33
|
[Metastatic spinal cord compression syndrome. A retrospective analysis of 297 patients].
|
Ugeskr Laeger
|
2006
|
0.75
|
|
34
|
|
Ugeskr Laeger
|
2017
|
0.75
|
|
35
|
A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
|
Ann Surg Oncol
|
2014
|
0.75
|
|
36
|
[Cancer from the exocrine pancreas].
|
Ugeskr Laeger
|
2013
|
0.75
|
|
37
|
[Treatment of Danish cancer patients in Hammelburg. A retrospective study of 34 patients].
|
Ugeskr Laeger
|
2004
|
0.75
|
|
38
|
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
|
Acta Oncol
|
2002
|
0.75
|
|
39
|
[Treatment of peritoneal carcinomatosis with pressurized intraperitoneal aerosol chemotherapy].
|
Ugeskr Laeger
|
2016
|
0.75
|
|
40
|
A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.
|
Acta Oncol
|
2004
|
0.75
|
|
41
|
Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer.
|
Acta Oncol
|
2013
|
0.75
|
|
42
|
[Adjuvant chemotherapy for patients with rectal cancer].
|
Ugeskr Laeger
|
2013
|
0.75
|
|
43
|
Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.
|
Acta Oncol
|
2010
|
0.75
|
|
44
|
[Oncological treatment of patients with pancreatic cancer].
|
Ugeskr Laeger
|
2010
|
0.75
|
|
45
|
[Chemotherapy and radiotherapy for inoperable pancreatic cancer. A survey of a Cochrane review].
|
Ugeskr Laeger
|
2007
|
0.75
|